Physician profile
Pierre Blanchard
NPI 1104889237
$4,104.74
in general payments reported to CMS, 2019-2025
36 companies · $819 in 2025
The $819 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $941 · 2020: $279 · 2021: $173 · 2022: $115 · 2023: $924 · 2024: $854 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,597.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $581.68 | 2019-2025 | |
| Glaxosmithkline, LLC. | $521.69 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $437.83 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $422.19 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $278.93 | 2019-2025 | Evenity, Otezla, Repatha |
| Janssen Pharmaceuticals, INC | $157.04 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $152.57 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Novo Nordisk INC | $136.97 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Dexcom, INC. | $134.54 | 2024-2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $124.47 | 2021 | |
| Phathom Pharmaceuticals, INC. | $118.65 | 2024-2025 | Voquezna |
| Daiichi Sankyo INC. | $92.63 | 2019-2023 | Injectafer |
| Corcept Therapeutics | $78.68 | 2025 | Korlym |
| Novartis Pharmaceuticals Corporation | $78.25 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.96 | 2019-2025 | Xifaxan |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $69.14 | 2023-2025 | Keveyis, Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.46 | 2024-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $60.66 | 2019 | |
| Astellas Pharma US INC | $55.30 | 2023-2024 | Veozah |
| Otsuka America Pharmaceutical, INC. | $53.12 | 2023-2024 | Rexulti |
| Insulet Corporation | $36.84 | 2025 | Omnipod |
| Abiomed | $36.76 | 2024-2025 | Impella |
| Verona Pharma, INC. | $36.16 | 2025 | Ohtuvayre |
| Lundbeck LLC | $34.06 | 2023-2024 | Rexulti |
| Avanir Pharmaceuticals, INC. | $32.25 | 2019 | |
| Abbott Laboratories | $31.02 | 2023 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $27.38 | 2023 | Quviviq |
| Mallinckrodt Hospital Products INC. | $26.19 | 2023-2024 | Terlivaz |
| Sanofi-Aventis U.S. LLC | $24.61 | 2019 | |
| Mylan Specialty L.P. | $22.35 | 2024 | Yupelri |
| Viatris Specialty LLC | $19.33 | 2025 | Yupelri |
| Vifor Pharma, INC. | $18.89 | 2023 | Veltassa |
| Ultragenyx Pharmaceutical INC. | $17.61 | 2024 | Crysvita |
| Sumitomo Pharma America, INC. | $16.88 | 2024 | Gemtesa |
| Exact Sciences Corporation | $16.40 | 2023 | Cologuard Collection Kit |
| Allergan, INC. | $14.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pierre Blanchard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.